Kosin Med J.  2018 Dec;33(3):402-408. 10.7180/kmj.2018.33.3.402.

Case of hyperosmolar hyperglycemic state by a sodium-glucose cotransporter 2 inhibitor

Affiliations
  • 1Department of Internal Medicine, Gwangmyeong Sungae Hospital, Gwangmyeong, Korea. dmbak@sungae.co.kr
  • 2Department of Internal Medicine, Sungae Hospital, Seoul, Korea.
  • 3Department of Internal Medicine, CHA Bundang Medical Center, CHA university, Bundang, Korea.

Abstract

Inhibitors of sodium-glucose cotransporters type 2 (SGLT2) are proposed as a novel approach for the management of type 2 diabetes mellitus. SGLT2 cotransporters are responsible for reabsorption of 90 % of the glucose filtered by the kidney. The glucuretic effect resulting from SGLT2 inhibition contributes to reduce hyperglycaemia and also assists weight loss and blood pressure reduction. In this study, we presented the case of a 59-year-old male who developed hyperosmolar hyperglycemic state (HHS), possibly caused by a sodium-glucose cotransporter 2 (SGLT2) inhibitor, a novel class of antihyperglycemic agents. This case highlights that HHS can develop in patients with diabetes treated with SGLT2 inhibitors

Keyword

Diabetes mellitus; Hyperosmolar hyperglycemic state; Sodium-glucose cotransporter 2 inhibitor

MeSH Terms

Blood Pressure
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose
Humans
Hyperglycemic Hyperosmolar Nonketotic Coma*
Hypoglycemic Agents
Kidney
Male
Middle Aged
Weight Loss
Glucose
Hypoglycemic Agents

Reference

1. Bakris G, Fonseca V, Sharma K, Wright E. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009; 75:1272–1277.
Article
2. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010; 95:34–42.
Article
3. Kim WJ, Kim SS. The side effects of sodium glucose cotransporter 2 (SGLT2) inhibitor. J Korean Diabetes. 2014; 15:158–162.
Article
4. FDA safety alert. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. 15 May 2015.
5. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35:1364–1379.
Article
6. Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, et al. Management of hyperglycemic crisis in patients with diabetes. Diabetes Care. 2001; 24:131–153.
7. Kitabchi AE, Umpierrez GE, Murphy MB, Kreisberg RA. Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care. 2006; 29:2739–2748.
Article
8. Ennis ED, Stahl EJVB, Kreisberg RA. The hyperosmolar hyperglycemic syndrome. Diabetes Rev. 1994; 2:115–126.
9. Delaney MF, Zisman A, Kettyle WM. Diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Endocrinol Metab Clin North Am. 2000; 29:683–705.
Article
10. Suzuki M, Takeda M, Kito A, Fukazawa M, Yata T, Yamamoto , et al. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes. 2014; 4:e125.
Article
11. Hamamoto H, Noda M. Body Weight Gain and Hyperphagia After Administration of SGLT-2 Inhibitor: A Case Report. Am J Case Rep. 2015; 16:863–867.
Article
12. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015; 38:1730–1735.
Article
Full Text Links
  • KMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr